Localization of GPSM2 in the Nucleus of Invasive Breast Cancer Cells Indicates a Poor Prognosis

Frontiers in Oncology

Bofang Liu¹  Xiaofang Che²  Yunpeng Liu²  Kezuo Hou²  Xiujuan Qu²  Zhe Zhang³  Qingjie Lv³  Xuejun Hu⁵  Mingming Deng⁶  Ye Zhang⁷ 

[1] Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China;Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China;Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China;Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, China;Graduate School of Peking Union Medical College, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China;The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China;

关键词: GPSM2;    DYNC1I1;    breast cancer;    prognosis;    subcellular localization;   

DOI  :  10.3389/fonc.2020.00227

来源: DOAJ

【 摘 要 】

Purpose: GPSM2 (G protein signaling modulator 2) was reported to be involved in the cell division of breast cancer cells. Additionally, cytoplasmic dynein may mediate the transport process of GPSM2. DYNC1I1 (Cytoplasmic dynein 1 intermediate chain 1) is the most common cargo-binding subunit of dynein. However, the relationship between GPSM2 and DYNC1I1 and its clinical value is unclear.Methods: Immunohistochemical staining was performed for assessment of GPSM2 and DYNC1I1 expression. Immunoprecipitation analysis was used to assess the interaction between GPSM2 and DYNC1I1.Results: GPSM2 was correlated with clinical characteristics of breast cancer patients and is an unfavorable independent prognostic factor. In addition, nuclear expression of GPSM2 is an unfavorable independent prognostic factor (HR = 2.658, 95% CI = 1.490–4.741, p = 0.001). GPSM2 and DYNC1I1 are known to form a complex in breast cancer cells. Patients who were positive for expression of both DYNC1I1 and GPSM2 presented with shorter recurrence-free survival than other patients. Importantly, patients with GPSM2 nuclear expression showed higher DYNC1I1 expression.Conclusion: GPSM2 was an independent prognostic factor in breast cancer and nuclear expression of GPSM2 was significantly associated with poor prognosis, which was related to the positive expression of DYNC1I1. Examination of both GPSM2 and DYNC1I1 is necessary to establish a prognosis in breast cancer patients.

【 授权许可】

Unknown